Phase I Study of PF-00477736 With Gemcitabine In Patients With Advanced Solid Malignancies
The study was closed to enrollment as of 17 May 2010 due to business reasons. The patient
on study continued treatment until 19 April 2011 when stopped for complete response.
Premature closure was not prompted by any safety or efficacy concerns.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum Tolerated Dose (MTD) of PF-00477736 When Administered in Combination With Gemcitabine
Up to Day 21 Cycle 1
Pfizer CT.gov Call Center
United States: Food and Drug Administration
|Pfizer Investigational Site||Blendora, California 91740|
|Pfizer Investigational Site||Bronx, New York 10461|